Rare Disease Drug Market Heats Up with Major Pharma Moves in December

　　【Pharmaceutical Network Industry Dynamics】In recent years, driven by multiple factors such as significant unmet clinical needs, favorable regulatory policies, and the gradual improvement of the drug security system, the orphan drug market has been rapidly gaining momentum. Since December 12, there have been substantial developments in the global orphan drug sector, including drug approvals, corporate mergers, and collaboration activities.
 

　　New Drug Approval
 

Recently, Waskyra, developed by Italy's Fondazione Telethon, has been approved for marketing. This is the FDA-approved gene therapy for treating Wiskott-Aldrich Syndrome (WAS). WAS is a rare and life-threatening genetic disorder that primarily affects boys, with an incidence of approximately 1 case per 250,000 male newborns. This is the first gene therapy approved by the FDA for treating patients with Wiskott-Aldrich Syndrome and received a similar recommendation for use in the EU last month.
 

On December 8, Gamida Cell's allogeneic umbilical cord blood cell therapy, Omisirge®, received approval for an additional indication of SAA, becoming the world’s first cell therapy for severe aplastic anemia (SAA) and the first dual-indication cell therapy with capabilities to treat both malignant and non-malignant blood disorders, covering SAA patients aged 6 years and above who lack matched donors. Previously, Omisirge® had been approved by the FDA in 2023 for umbilical cord blood transplantation in patients aged 12 years and older with hematologic malignancies undergoing myeloablative conditioning, to reduce neutrophil recovery time and lower infection risks.
 

On December 9, AMT-253, an MUC18 ADC drug discovered by Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd., was proposed to be included in the breakthrough therapy designation for locally advanced melanoma and other melanomas that have failed first-line treatment. The drug utilizes an independent ADC platform, and its Phase I clinical data has been reported in both China and Australia. It is expected to become the company’s first drug to initiate a pivotal clinical trial. On the same day, JNJ-78278343 Injection from Johnson & Johnson was also proposed for inclusion in the breakthrough therapy category. It is intended for patients with metastatic castration-resistant prostate cancer who have undergone specific treatments. This drug is the world's first KLK2-targeted drug to enter Phase III clinical trials.
 

　　Mergers and Acquisitions Financing
 

On December 17, Aeovian, a U.S.-based rare disease drug developer, announced the completion of a $55 million Series B financing round. This round was co-led by CTI Life Sciences Fund and Luma Group, with participation from multiple institutions including Hevolution, Sofinnova Investments, and venBio Partners. Aeovian focuses on developing highly selective mTOR inhibitors to improve clinical outcomes for patients with age-related rare diseases. The proceeds will be used to advance clinical trials and drug development for its core pipeline.
 

In December, Mirum Pharmaceuticals announced the acquisition of Bluebird Therapeutics for $820 million, gaining global rights to the monoclonal antibody drug Brelevocept upon completion of the transaction. As a fully human monoclonal antibody in late-stage clinical development, the drug has demonstrated clear therapeutic potential and received Breakthrough Therapy Designation from the U.S. FDA for the treatment of chronic hepatitis D virus (HDV), as well as PRIME designation from the European Medicines Agency (EMA). Mirum plans to apply for regulatory approval in the U.S. by 2027, and this acquisition will rapidly strengthen its portfolio in the field of rare liver disease treatments.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.